Evidence map›Paper›PMID 40091023›Full record

ArticleBMC infectious diseases2025

Optimal treatment of Imipenem and meropenem against bloodstream infections caused by the Citrobacter spp.

Lushun Jiang, Jiaheng Fang, Jiajie Zhang, Kanghui Zhang, Junpeng Yue, Kaixuan Dong, Jiaying Shen, Yunqing Qiu, Wei Yu

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in BMC infectious diseases, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Lushun Jiang *State Key Laboratory for Diagnosis and Treatment of Infectious Diseases, Collaborative Innovation Center for Diagnosis and Treatment of Infectious Diseases, The First Affiliated Hospital, National Clinical Research Center for Infectious Diseases, Zhejiang University School of Medicine, Hangzhou, China.
Jiaheng Fang *Department of gastroenterology, Hangzhou Normal University Affiliated Hospital, Hangzhou, China.
Jiajie ZhangCenter for General Practice Medicine, Department of Infectious Diseases, Affiliated People's Hospital, Zhejiang Provincial People's Hospital, Hangzhou Medical College, Hangzhou, China.
Kanghui ZhangZhejiang University, Hangzhou, China.
Junpeng YueZhejiang University, Hangzhou, China.
Kaixuan DongZhejiang University, Hangzhou, China.
Jiaying ShenZhejiang University, Hangzhou, China.
Yunqing QiuState Key Laboratory for Diagnosis and Treatment of Infectious Diseases, Collaborative Innovation Center for Diagnosis and Treatment of Infectious Diseases, The First Affiliated Hospital, National Clinical Research Center for Infectious Diseases, Zhejiang University School of Medicine, Hangzhou, China. qiuyq@zju.edu.cn.
Wei YuState Key Laboratory for Diagnosis and Treatment of Infectious Diseases, Collaborative Innovation Center for Diagnosis and Treatment of Infectious Diseases, The First Affiliated Hospital, National Clinical Research Center for Infectious Diseases, Zhejiang University School of Medicine, Hangzhou, China. wyu@zju.edu.cn.

Funding

Department of Health of Zhejiang province 2023KY713
6 · The paper itself

Abstract

objectivesThis work was to investigate the optimal treatments of imipenem (IPM) and meropenem (MEM) against bloodstream infections (BSIs) caused by Citrobacter spp.

methodsA total of 230 nonduplicate BSIs Citrobacter spp. were collected from 2014 to 2020 in three hospitals in Zhejiang Province in China. The minimum inhibitory concentrations (MICs) of 17 antibiotics were determined. Monte Carlo simulation (MCS) was used to investigate the cumulative fraction of response (CFR) of 8 regimens of IPM and 10 regimens of MEM.

resultsC. freundii (Cfr) was the predominant epidemic isolate (83.9%, 193/230). The resistance rates to IPM and MEM showed an increasing trend from 2015 to 2019. Fosfomycin showed excellent activity from 2014 to 2020. The probability of target attainment of IPM and MEM by prolonged 3 h infusion therapy (PIT) was higher than that by traditional 0.5 h (h) infusion therapy (TIT) during the same administration dosage. The CFR of all IPM regimes was above 90%, while MEM with 500 mg q8h was lower than 90%, especially for Cfr.

conclusionsCfr is the most common BSIs. Citrobacter spp. PIT is more adequate to provide activity against BSIs Citrobacter spp., especially for IPM.

Indexed as

Anti-Bacterial AgentsBacteremiaCitrobacterEnterobacteriaceae InfectionsImipenemMeropenemChinaHumansMicrobial Sensitivity TestsMonte Carlo MethodAnti-Bacterial AgentsImipenemMeropenemCitrobacter sppImipenemMeropenemMonte carlo simulationOptimization of treatment

Identifiers

PMID40091023
PMCPMC11912752

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.